Long noncoding RNAs as novel serum biomarkers for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis

Zheng, Chuanchao; Hao, Haibin; Chen, L.; Shao, Jianghua

doi:10.1007/s12094-017-1626-1

Cited by 26 publications

(23 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Alpha fetal protein (AFP) has been widely used as a diagnostic marker for HCC, but its sensitivity and specificity are suboptimal [ 92 , 93 ]. lncRNAs with a significantly aberrant expression profile in HCC tissues as opposed to healthy liver may hold great potential as diagnostic markers [ 94 ]. Some lncRNAs may be stably present in body fluids such as plasma and their expression levels are consistently associated with the progression of HCC [ 94 ].…”

Section: Role Of Lncrnas In the Regulation Of Liver Cancer Stem Cellsmentioning

confidence: 99%

Dysregulated long noncoding RNAs (lncRNAs) in hepatocellular carcinoma: implications for tumorigenesis, disease progression, and liver cancer stem cells

et al. 2017

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the most common malignant tumours with a poor prognosis worldwide. While early stage tumours can be treated with curative approaches such as liver transplantation or surgical resection, these are only suitable for a minority of patients. Those with advanced stage disease are only suitable for supportive approaches and most are resistant to the conventional chemotherapy or radiotherapy. Liver cancer stem cells (LCSCs) are a small subset of cancer cells with unlimited differentiation ability and tumour forming potential. In order to develop novel therapeutic approaches for HCC, we need to understand how the cancer develops and why treatment resistance occurs. Using high-throughput sequencing techniques, a large number of dysregulated long noncoding RNAs (lncRNAs) have been identified, and some of which are closely linked to key aspects of liver cancer pathology, progression, outcomes and for the maintenance of cancer stem cell-like properties. In addition, some lncRNAs are potential biomarkers for HCC diagnosis and may serve as the therapeutic targets. This review summarizes data recently reported lncRNAs that might be critical for the maintenance of the biological properties of LCSCs.

show abstract

Section: Role Of Lncrnas In the Regulation Of Liver Cancer Stem Cellsmentioning

confidence: 99%

Dysregulated long noncoding RNAs (lncRNAs) in hepatocellular carcinoma: implications for tumorigenesis, disease progression, and liver cancer stem cells

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The technique for detection and measurement of specific serum lncRNAs has become feasible, which provides a new method without invasiveness for the identification of new biomarker for cancer. Recent studies found that serum lncRNAs are useful for the diagnosis of multiple types of cancer, such as bladder cancer [ 69 ], liver cancer [ 70 ], cervical cancer [ 71 ], gastric cancer [ 72 ], colorectal cancer [ 73 , 74 ] and breast cancer [ 75 ] etc, these serum lncRNAs may even serve as prognostic biomarkers [ 69 , 72 , 74 ]. Serum lncRNAs in RCC patients are also deregulated.…”

Section: Lncrnas In Rccmentioning

confidence: 99%

Long non-coding RNAs in renal cell carcinoma: A systematic review and clinical implications

Wang

Liu

et al. 2017

Oncotarget

View full text Add to dashboard Cite

Renal cell carcinoma is one of the most common malignancy in adults, its prognosis is poor in an advanced stage and early detection is difficult due to the lack of molecular biomarkers. The identification of novel biomarkers for RCC is an urgent and meaningful project. Long non-coding RNA (lncRNA) is transcribed from genomic regions with a minimum length of 200 bases and limited protein-coding potential. Recently, lncRNAs have been greatly studied in a variety of cancer types. They participate in a wide variety of biological processes including cancer biology. In this review, we provide a new insight of the profiling of lncRNAs in RCC and their roles in renal carcinogenesis, with an emphasize on their potential in diagnosis, prognosis and potential roles in RCC therapy.

show abstract

“…As we know that lncRNA studies are still in their infancy and the functions remain unclear. Up to now, more and more literature has proved that lncRNA expressions are involved in cancer metastasis (5,6). Brain cytoplasmic RNA 1 (BCYRN1), also called BC200, ordinarily cannot be detected in normal tissue, except for in the primate nervous system (7).…”

Section: Introductionmentioning

confidence: 99%

Long non-coding RNA BCYRN1 promotes the proliferation and metastasis of cervical cancer via targeting microRNA-138 inï¿½vitro and inï¿½vivo

et al. 2018

View full text Add to dashboard Cite

Abstract. Cervical cancer is one of the most malignant types of tumor and the fourth leading cause of cancer-associated mortality in females worldwide. High expression of brain cytoplasmic RNA 1 (BCYRN1) has been detected in various tumors. The present study aimed to investigate the effect of BCYRN1 in the viability and motility of cervical cancer, and the relevant mechanism. The results demonstrated that BCYRN1 was upregulated in cervical cancer tissues compared with normal tissues. Elevated levels of BCYRN1 were also detected in three human cervical cancer cell lines (SiHa, HeLa and CaSki) compared with non-cancerous ectocervical epithelial cell line (Ect1/E6E7). The expression of BCYRN1 was suppressed following transfection with small interfering RNA (siRNA) in HeLa cells. The silence of BCYRN1 significantly reduced cell viability and motility. Furthermore, microRNA (miR)-138 was predicted as a direct target of BCYRN1 and the expression of miR-138 was elevated in HeLa cells transfected with BCYRN1 siRNA. Subsequently, elevated levels of miR-138 were suppressed by transfection with miR-138 inhibitor in HeLa cells pretreated with BCYRN1 siRNA. The targeting association between BCYRN1 and miR-138 was supported by luciferase reporter assays. Additionally, BCYRN1 siRNA partially counteracted the effect of miR-138 inhibitor on promoting cell viability and mobility in HeLa cells. Finally, the in vivo experiment verified that BCYRN1 siRNA was able to prevent tumor growth, and reduced the expression of migration marker proteins metalloproteinase 2 and vascular endothelial cell growth factor, with enhanced expression levels of miR-138. These results suggest that lncRNA BCYRN1 promotes the proliferation and invasion of cervical cancer via targeting miR-138.

show abstract

Long noncoding RNAs as novel serum biomarkers for the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis

Abstract: LncRNAs were a high diagnostic value for HCC and its expression could potentially be used as auxiliary biomarker in confirming HCC.

Cited by 26 publications

References 41 publications

Dysregulated long noncoding RNAs (lncRNAs) in hepatocellular carcinoma: implications for tumorigenesis, disease progression, and liver cancer stem cells

Dysregulated long noncoding RNAs (lncRNAs) in hepatocellular carcinoma: implications for tumorigenesis, disease progression, and liver cancer stem cells

Long non-coding RNAs in renal cell carcinoma: A systematic review and clinical implications

Long non-coding RNA BCYRN1 promotes the proliferation and metastasis of cervical cancer via targeting microRNA-138 inï¿½vitro and inï¿½vivo

Contact Info

Product

Resources

About